Survey and analysis of the prevalence of tobacco use among patients with severe mental illness at a tertiary specialized psychiatric medical center in China

中国某三级专科精神医疗中心重性精神疾病患者吸烟情况调查与分析

阅读:2

Abstract

BACKGROUND: In China, the coexistence of mental illness and tobacco dependence is a major public health issue. With around 300 million smokers and over one million annual smoking-related deaths, the resulting social and economic burdens are considerable. METHODS: A cross-sectional study design was employed to gather data on tobacco use, readiness to quit smoking, and nicotine dependence from a random sample of 738 patients diagnosed with severe mental illness. Data analysis, which included descriptive statistics and multivariate logistic regression analysis, was conducted via SPSS 27.0. RESULTS: The findings revealed that the smoking prevalence among patients with severe mental illness was 52.03%, significantly higher than that of the general population. Multifactorial logistic regression analysis indicated that male gender(OR=10.041, 95% CI: 6.499-15.513), Han ethnicity(OR=3.263, 95% CI: 1.053-10.108), worse economic status (OR=2.540, 95% CI: 1.424-4.529), family history of smoking (OR=6.474, 95% CI: 4.211-9.952), outpatient status(OR=2.294, 95% CI: 1.433-3.674), family history of mental illness (OR=1.756, 95% CI: 1.129-2.731), history of drug exposure(OR=2.074, 95% CI: 1.244-3.458), and history of alcohol consumption(OR=5.216, 95% CI: 3.037-8.960) were independent risk factors for smoking in this patient group. Furthermore, there were significant differences in nicotine dependence levels across different psychiatric diagnoses, with patients diagnosed with schizophrenia and bipolar disorder exhibiting higher levels of nicotine dependence compared to those with paranoid disorder who showed lower levels. CONCLUSIONS: The study elucidates the complex nature and critical determinants of tobacco use patterns among individuals with severe mental illness, providing a solid scientific foundation for developing targeted intervention strategies. CHINA CLINICAL TRIAL REGISTRY REGISTRATION NUMBER: ChiCTR2400088459.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。